Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
StopBleed Pro
- Development stage
- Preclinical
- Lead developer
- Miraqules Medsolutions
- Administration
- Topical
01
Overview
StopBleed Pro is a topical hemostatic medical device developed by Miraqules Medsolutions. It is designed for the management of severe bleeding in emergency, trauma, and surgical situations, particularly for narrow entry wounds. The device utilizes a nano-biopolymer platform containing polysaccharides derived from shrimp shells (chitosan). It mimics the body's natural clotting process by forming fibrin-like threads and employs charge-based clotting acceleration and high absorption rates to achieve hemostasis in less than a minute. The product is designed for atraumatic removal and comes in a pellet format with a specialized applicator.
- Brand names
- StopBleed Pro
- Other names
- StopBleed
Beyond the preview
Go deeper on StopBleed Pro.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on StopBleed Pro.